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Background: Bone marrow-derived endothelial stem cells participate in vascular repairs. Numbers of circulating
endothelial progenitor cells (cEPCs) are associated with atherosclerosis. Fibrinogen plays a key role in atherosclerosis.
Objective was to assess if cEPC counts were associated with atherosclerotic intracranial artery stenosis (IAS).
Methods: Three hundred subjects (108 patients with stroke and IAS (IAS), 120 control patients with stroke without
IAS (CP), and 72 healthy controls (HC)) were retrospectively analyzed. cEPCs were identified and counted by flow
cytometry using CD34, CD133 and KDR. Plasma fibrinogen was measured by immunoturbidimetry. cEPC counts
were compared between the three groups.
Results: cEPC numbers were significantly higher in IAS (0.059 ± 0.031%) than in CP (0.026 ± 0.012%) (P < 0.001) and
HC (0.021 ± 0.011%) (P < 0.001), but without difference between CP and HC (P = 0.401). Multiple logistic regression
analysis showed that cEPC levels (OR 3.31, 95%CI 1.26-8.87, P = 0.025; IAS vs. CP) were independent markers of IAS
after adjustment for hypertension, diabetes and smoking. No significant correlation between cEPC counts and
plasma fibrinogen levels was observed (P > 0.05).
Conclusion: cEPC numbers were associated with degrees of IAS. This measurement may be useful for non-invasive
evaluation of atherosclerotic IAS.
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Intracranial arterial stenosis (IAS) is an important cause of
stroke. The number of intracranial symptomatic vessels
and their stenosis degree is associated with a higher risk of
stroke recurrence and other major ischemic events [1-4].
However, the mechanisms for atherosclerosis initiation
and progression in intracranial large arteries are still ill
understood. First, intracranial atherosclerosis may be char-
acterized by multiple stenoses of cerebral large arteries,
which may result in chronic brain hypoperfusion, respon-
sible for an enhanced angiogenic response [5]. Secondly,
endothelial repair may be crucial for atherosclerosis pro-
gression in intracranial large arteries [6]. In addition, bone* Correspondence: KangXixiongmedsci@163.com
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reproduction in any medium, provided the ormarrow-derived endothelial stem cells can differentiate
into mature vascular endothelial cells and participate in
vascular repair [7].
Many factors, including proinflammatory interleukin
(IL)-8 [8] and chemokine monocyte chemoattractant
protein-1 (MCP-1) [9], are important for endothelial pro-
genitor cells (EPCs) mobilization. Furthermore, even if
their exact role is not yet completely understood, circulat-
ing EPCs (cEPCs) are involved in vascular pathologies
[10-13]. Elevated cEPC levels have been associated with
atherosclerotic diseases, but the results are conflicting
[14-20]. Serum IL-8 and MCP-1 levels are elevated in
pathological conditions, along with elevated numbers of
cEPCs [12,18,21-23]. Fibrinogen exposure can result in
up-regulation of expression and secretion of MCP-1 and
IL-8 in endothelial [24] and dendritic cells [25]. Fibrinogen
plays a key role in the development of atherosclerosis [26].This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation between plasma fibrinogen levels, cEPCs and IAS.
This present study explored the association between cEPC
numbers and IAS, and if there was a correlation between
EPC and fibrinogen levels. cEPCs might be a disease
marker in IAS, and may also be a treatment target in IAS.
Methods
Patient demographics and exclusion criteria
This study was approved by the Ethics Committee of the
Beijing Tiantan Hospital Affiliated to the Capital Medical
University, China (approval #KYLW2013-004-01), and in-
dividual informed consent was waived. A cohort of 108 pa-
tients with symptomatic IAS, 120 control patients without
IAS (CP) and 72 healthy controls (HC) from September
2011 to July 2012 were retrospectively analyzed. IAS
and CP patients were selected from patients with a first-
ever ischemic stroke in the neurology department of the
Beijng Tiantan Hospital. Intra- and extracranial cerebral
large arteries were evaluated by trans-cranial Doppler
(TCD) in all subjects. IAS was reconfirmed by digital sub-
traction angiography (DSA). Exclusion criteria were: 1)
modified Rankin Scale score > 2; 2) emboligenic cardiopa-
thy; 3) cancer diagnosis; 4) chronic inflammatory disease;
or 5) non-atherosclerotic intracranial stenosis, such as
Sneddon syndrome, Moya-Moya disease, postradiotherapy
angiopathy, and vasculitis.
Image acquisition
TCD was performed using a MultiDop-X/TCD (Compu-
medics DWL, Singen, Germany), with a hand-held trans-
ducer in a range-gated, pulsed-wave mode at a frequency
of 2 Mhz. IAS was diagnosed according to validated cri-
teria [27]. Cervical intracranial artery (ICA) atherosclerosis
was regarded as any ICAs showing a stenosis ≥50%.
Intracranial stenosis was reconfirmed by DSA (Innova
3100IQ, GE Healthcare, Waukesha, WI, USA,) and was
defined as a focal stenosis ≥50% in luminal reduction af-
fecting the main cerebral large arteries. Stenosis was clas-
sified as severe (≥70%) or non-severe (<70%), based on the
symptomatic narrowed artery [1].
Flow cytometry
Peripheral blood (2 mL) was collected in tubes containing
K2-EDTA on the 7
th day after acute onset and was proc-
essed within 1 hour of collection. Peripheral blood mono-
nuclear cells (PBMCs) were isolated by density gradient
centrifugation using Ficoll-Hypaque (Amersham, GE
Healthcare, Waukesha, WI, USA), washed with PBS, and
counted for recovery and viability using Trypan Blue. Since
EPCs are characterized by the co-expression of CD34,
CD133 and KDR [28,29], we determined the proportion of
cEPCs in PBMCs by flow cytometry using a triple staining
with fluorescein-conjugated monoclonal antibodies againstthese markers. Briefly, PBMCs (1 × 106) were incubated
with CD34-PerCP-Cy5.5 (Becton Dickinson, Franklin Lake,
NJ, USA), CD133-PE (eBioscience, San Diego, CA, USA),
and KDR-Alexa Flour647 (Becton Dickinson, USA) for
25 min at 4°C in a dark room. Non-specific binding
was determined by staining an aliquot of cells with
fluorescein-conjugated IgG1 and IgG2a isotype con-
trols (Becton Dickinson, Franklin Lake, NJ, USA).
After washing once with PBS, cells were fixed with 1%
paraformaldehyde and analyzed using a FACS Calibur
flow cytometer (Becton Dickinson, USA). We gated CD34+
peripheral blood cells in the mononuclear cell fraction,
followed by the examination of the resulting subpopula-
tion for expression of KDR, CD133 or both. The frequency
of peripheral blood cells positive for these markers was
determined by a 2-dimensional side-scatter fluorescence
dot-plot analysis, after appropriate gating. A minimum
of 50,000 events was acquired for each sample. Data
were analyzed using the embedded Cellquest software.
EPC numbers were expressed as the proportion of total
PBMCs.
Plasma fibrinogen levels
On the 7th day after acute onset, peripheral blood (3 mL)
was collected in tubes containing sodium citrate to meas-
ure plasma fibrinogen levels, using a CA5000 Coagulation
Analyzer (Sysmex, Kobe, Japan).
Statistical analysis
Inter-groups differences were assessed using the χ2, Fisher’s
exact tests, Student’s t-test or one-way ANOVA with post
hoc analysis. Pearson correlation analysis was used to
analyze the relationship between plasma fibrinogen levels
and cEPC numbers. A multiple logistic regression model
was used to identify independent IAS markers (variables
with a P-value <0.05 in univariate testing were included);
adjustment for age, gender, and vascular risk factors was
also performed. Results are expressed as adjusted odds ra-
tios (OR) and corresponding 95% confidence intervals (CI).
P < 0.05 was considered to be statistically significant. All




Table 1 presents subjects’ demographics and risk factor
characteristics. The proportion of patients with hyperten-
sion, diabetes and tobacco use were higher in the IAS
group (all P < 0.001). A total of 206 stenoses in 108 IAS
patients were identified.
Endothelial progenitor cells
The proportions of CD34+ cells were 0.293 ± 0.182% in
HC, 0.364 ± 0.201% in CP, and 0.553 ± 0.311% in IAS
Table 1 Patients’ demographic and risk factor characteristics
HC (n = 72) CP (n = 120) IAS (n = 108) PΔ P# P*
Age, mean ± SD 56.0 ± 10.2 56.9 ± 7.6 61.5 ± 12.1 0.652 0.132 0.281
Gender (female), n (%) 28 (38.9) 48 (40.0) 48 (44.4) 0.879 0.460 0.497
BMI, Kg/m2 24.2 ± 4.2 26.1 ± 8.6 26.9 ± 8.9 0.035 0.031 0.756
sBP, mmHg 123.2 ± 17.7 134.1 ± 16.54 138.1 ± 18.72 0.065 0.036 0.452
dBP, mmHg 81.6 ± 10.1 83.52 ± 12.05 85.6 ± 10.1 0.396 0.041 0.462
TG, mmol/l 1.325 ± 0.35 1.446 ± 0.77 1.504 ± 0.83 0.689 0.478 0.837
TC, mmol/l 3.935 ± 0.93 4.078 ± 0.68 4.697 ± 0.85 0.696 0.019 0.089
HDL, mmol/l 1.198 ± 0.26 1.05 ± 0.16 0.955 ± 0.15 0.099 0.003 0.297
LDL, mmol/l 2.43 ± 0.81 2.626 ± 0.55 2.624 ± 0.78 0.623 0.601 0.991
Glu, mmol/l 5.75 ± 1.06 6.059 ± 3.32 5.58 ± 0.97 0.745 0.748 0.555
CRP, mg/l 0.65 (0.31-1.37) 1.55 (0.65-2.71) 2.75(1.2-3.25) 0.021 <0.001 0.012
Hypertension, n (%) 0 30 (25.0) 84 (77.8) - - <0.001
cEPCs (%)
CD34+ 0.293 ± 0.182 0.364 ± 0.201 0.553 ± 0.311 0.028 0.009 0.019
CD34+/CD133+ 0.098 ± 0.032 0.113 ± 0.064 0.246 ± 0.142 0.382 <0.001 <0.001
CD34+/CD133+/KDR+ 0.021 ± 0.011 0.026 ± 0.012 0.059 ± 0.031 0.401 <0.001 <0.001
Diabetes, n (%) 0 6 (5.0) 24 (22.2) - - <0.001
Hyperlipidemia, n (%) 0 18 (15.0) 24 (22.2) - - 0.160
CAD, n (%) 0 12 (10.0) 18 (16.7) - - 0.137
Smoking, n (%) 0 48 (40.0) 78 (72.2) - - <0.001
Drug treatment - -
Statin, n (%) 4 (5) 31 (26) 35 (32) - - 0.316
ACE inhibitor, n (%) - 20 (17) 31 (29) - - 0.029
Angiotensin II receptor blocker, n (%) - 3 (2) 2 (2) - - 0.739
Beta blocker, n (%) - 10 (8) 13 (12) - - 0.345
Calcium antagonist, n (%) - 19 (16) 34 (32) - - 0.005
PΔ: CP vs. HC P#: IAS vs. HC P*: IAS vs. CP.
sBP: systolic blood pressure; dBP: diastolic blood pressure.
HC, healthy controls; CP, control patients; IAS, patients with intracranial artery stenosis; CAD: coronary artery disease.
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cells were 0.098 ± 0.032% in HC, 0.113 ± 0.064% in CP,
and 0.246 ± 0.142% in IAS patients (P < 0.001 for IAS vs.
CP and HC; P = 0.382 for CP vs. HC) (Table 1). The pro-
portions of CD34+/CD133+/KDR + cEPCs among total
PBMCs were 0.021 ± 0.011% in HC, 0.026 ± 0.012% in CP,
and 0.059 ± 0.031% in IAS patients (Figure 1A). The num-
ber of CD34+/CD133+/KDR + cEPCs was significantly
higher in patients with IAS than in CP and HC (all P <
0.001), but no significant difference was observed in
cEPCs between CP and HC (P = 0.401).
Multiple logistic regression showed that the numbers of
cEPCs (OR 3.31, 95%CI 1.26-8.87, p = 0.025; IAS vs. CP)
were an independent IAS marker after adjustment for
hypertension, diabetes, smoking and CRP levels (Table 2).
In HC, numbers of cEPCs were not different between
subjects <60 (n = 39) and ≥60 years old (0.018 ± 0.009% vs.
0.022 ± 0.011%, p = 0.476). However, cEPCs numbers inIAS patients <60 (n = 60) was significantly higher than in
patients ≥60 years old (0.077 ± 0.035% vs. 0.045 ± 0.016%
P = 0.019) (Figure 1B). Among subjects ≥60 years old,
cEPCs numbers in the IAS group were 2.1 times higher
than in HC. Among subjects <60 years old, cEPCs num-
bers in the IAS group were 4.3 times higher than in HC.
There was no difference between male and female patients
(0.063 ± 0.039 vs. 0.055 ± 0.032%, P = 0.198). Diabetic pa-
tients had significantly less EPCs than non-diabetics
(0.043 ± 0.019 vs. 0.065 ± 0.042%, P = 0.024) (Figure 1C).
Association between cEPC numbers and clinical
characteristics in IAS patients
As shown in Table 3, cEPC numbers were significantly
higher in patients with ≥70% stenosis than in those
with <70% stenosis (0.091 ± 0.035% vs. 0.052 ± 0.022%,
P = 0.012). There was no significant difference in cEPCs
between 1, 2 and >2 stenosed artery (P = 0.578).
Figure 1 cEPCs proportions across different groups. (A) cEPC
levels in the peripheral blood of HC, CP and IAS (*P < 0.01, IAS vs.
HC; # P < 0.01, IAS vs. CP). Rresults are presented as mean ± SD.
(B) Differences in cEPC levels in the peripheral blood of HC and IAS
according to age (*P < 0.05, <60 vs. ≥60 years old in IAS patients).
Results are presented as mean ± SD. (C) Differences in cEPCs levels
of IAS according to the diabetes status (*P < 0.05 vs. diabetics).
Table 2 Multivariate model of characteristics
hypothesized to be associated with IAS (IAS vs. CP)
Characteristic Odds ratio 95% CI P
Hypertension (yes vs. no) 1.38 0.97-2.59 0.045
Diabetes (yes vs. no) 1.73 1.15-2.89 0.017
Tobacco use (yes vs. no) 2.23 1.02-5.15 0.038
CRP (per 1 mg/l increase) 2.25 1.22-3.96 0.029
cEPCs counts (per 1% increase) 3.31 1.26-8.87 0.025
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fibrinogen levels
Compared with HC, CP and IAS patients showed higher
plasma fibrinogen levels (3.09 ± 0.51 mg/L vs. 3.62 ± 0.52
and 3.84 ± 0.62 mg/L, respectively) (Figure 2). No signifi-
cant correlation was detected between cEPC numbers and
plasma fibrinogen levels in the three groups (HC: r = 0.29,
P = 0.21; CP: r = 0.19, P = 0.54; IAS: r = 0.23, P = 0.32).
Discussion
Our study demonstrated that IAS patients had an in-
creased mobilization of cEPCs in peripheral circulation.
Moreover, cEPC levels were higher in patients with higher
stenosis (≥70%). However, we did not observe any correl-
ation between cEPC and fibrinogen levels. Nevertheless,
cEPC counts could be used to assess the extent of IAS.
The association between the number of cEPCs and clin-
ical manifestations of atherosclerosis has been previously
reported. Morishita et al. [12] observed that the number
of cEPCs was a marker of severity of peripheral artery dis-
eases. In addition, Rafat et al. [21] showed that the number
of EPCs was significantly higher in patients with athero-
sclerotic cerebral vascular disease compared with healthy
controls. Chu et al. [22] showed that cEPC counts were as-
sociated with known markers of vasculopathy (HbA1c and
homocysteine) in acute stroke patients. Pelliccia et al. [18]
showed that cEPC numbers were associated with progno-
sis in patients with percutaneous coronary intervention
(PCI)-treated stable angina, and that PCI-treated stable
angina patients with restenosis had higher cEPC numbersTable 3 cEPC levels according to stenosis degree and the





<70% 48 0.052 ± 0.022




1 30 0.065 ± 0.024
2 26 0.058 ± 0.033
>2 52 0.067 ± 0.044
Figure 2 Differences in fibrinogen levels between the three
groups (*P < 0.05 vs. healthy controls). Results are presented
as mean ± SD.
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differences in circulating CD34+ cells in patients with
major cerebral artery occlusion (or sever stenosis), and
Sobrino et al. [31] showed that elevated cEPC numbers in-
dicated an improved prognosis in stroke patients. This
might be explained by the fact that CD34 is also present
on mature endothelial cells and monocytes, and cannot be
used alone to characterize bone marrow-derived immature
cells. Although the exact phenotype of cEPCs is still con-
troversial, the concomitant presence of CD34, CD133 and
KDR seems to be well-supported [28,29], and we used this
profile in the present study. Our results suggest that
cEPCs, defined as CD34+/CD133+/KDR + cells, may indi-
cate a disorderly growth of vascular endothelium in differ-
ent intracranial lesions. Thus, these cells may be a useful
marker for IAS. However, the association between cEPCs
and markers of atherosclerosis remains controversial, as
shown by previous studies [12,18,21-23], and the results
from the present study about the lack of association be-
tween cEPC and fibrinogen levels.
However, these previous studies did not discriminate be-
tween intracranial or extracranial artery stenosis. One of
our previous studies suggested that there were obvious
differences between atherosclerosis lesions in intra- and
extracranial cerebral large arteries [32]. Thus, ideally,
intra- and extracranial atherosclerosis should be studied
separately. In the present study, we observed that cEPC
levels in patients with IAS were significantly higher than
in HC. Moreover, cEPC numbers in IAS were significantly
higher compared with stroke patients without IAS. These
results indicate that abnormal EPC mobilization may play
a role in the development and presence of IAS. Indeed,
under normal circumstances, cEPCs participate in the for-
mation and repair of vascular endothelial cells [7]. How-
ever, pathological conditions increasing EPCs activitymight lead to excessive angiogenesis and artery narrowing.
Ischemia and hypoperfusion induce endogenous VEGF
production, which is an important factor for EPC
mobilization [33]. However, ischemia symptoms are simi-
lar between patients with or without IAS. Therefore, we
suppose that ischemia is not the only reason for higher
cEPC numbers observed in patients with IAS. Our results
also showed that cEPC numbers were not associated with
the number of stenotic intracranial arteries, but with the
degree of IAS, suggesting that stenosis degree and number
of symptomatic intracranial arteries may be determined by
different factors.
Increasing age has been shown to be associated with
reduced cEPC levels in patients with coronary artery
disease (CAD) [14]. In this present study, no difference
was observed in cEPC levels between age groups (<60
and ≥60 years old) in HC. However, we observed that
cEPC numbers were significantly higher in IAS pa-
tients <60 years old compared with ≥60. These results
indicated that higher cEPC numbers might play a more
important role in atherosclerosis progression in youn-
ger patients.
Many factors, including growth factors, proinflamma-
tory cytokines, chemokines, hormones and lipid-lowering
and antidiabetic drugs, have been regarded as important
factors involved in EPC mobilization [34]. Fibrinogen is an
inflammatory marker and is closely related with athero-
sclerosis [24-26]. To the best of our knowledge, no study
focused on the association between fibrinogen levels and
cEPCs mobilization. Our study showed that serum fibrino-
gen levels were higher in IAS patients and CP compared
with HC, but that there was no difference between IAS
and CP, suggesting that fibrinogen might not be a key fac-
tor stimulating cEPCs mobilization specifically in IAS.
This was further supported by the lack of correlation be-
tween cEPC numbers and plasma fibrinogen levels in IAS
and CP.
Studies on the relationship between cEPC numbers and
coronary artery stenosis (CAS) are conflicting. It was re-
ported that cEPC numbers were decreased in CAD with
significant CAS [15]. However, Guven et al. [16] observed
that cEPC numbers were higher in patients with signifi-
cant CAS compared with patients without significant
CAS. This might be due to the criteria used to identify
specific angiogenic cell subpopulations and to evaluate
CAD. These results in combination with our study sug-
gested that the difference in the definition of cEPCs might
greatly influence the correlation of cEPCs with the specific
diseases such as IAS and CAS.
The present study has some limitations. First, even if we
used a widely recognized method to identify cEPCs, there
is a lack of standardization for this measurement, which
could affect the results. Second, we cannot rule out the
possibility that the elevation in CD34+ and CD133+ cells
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levels and peripheral blood cells mobilization. Third, it is
possible that drugs taken by the patients might affect the
proportions of EPCs. Fourth, we did not measure inflam-
mation and stress markers in stroke patients, only CRP.
Lastly, our sample size limits the application of our data in
current clinical practice. Therefore, our results need to be
confirmed in large-scale trials. Despite these limitations,
our results revealed that higher cEPC numbers were
closely associated with IAS.
Conclusion
Our study demonstrated that higher cEPC numbers were
involved in IAS. It also indicated that fibrinogen may not
be the main mediator for cEPCs mobilization in IAS.
More studies are required to assess the key factors in-
volved in cEPCs mobilization in IAS, and to evaluate the
effects of IAS treatments on cEPC numbers.
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